Skip to content

R&D at other companies

Amgen logo
AmgenAMGN
$1.72B+15.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.54B+16.3%
Janux Therapeutics logo
Janux TherapeuticsJANX
$26.81M+7.0%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$46.66M+9.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$33.99M-17.5%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$88.51M+44.6%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's R&D?
Xencor (XNCR) reported R&D of $64.67M in Q1 2026.
How has Xencor's R&D changed year-over-year?
Xencor's R&D increased by 10.4% year-over-year, from $58.58M to $64.67M.
What is the long-term trend for Xencor's R&D?
Over 4 years (2021 to 2025), Xencor's R&D has grown at a 5.6% compound annual growth rate (CAGR), from $192.51M to $239.43M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.